Zobrazeno 1 - 10
of 25
pro vyhledávání: '"M R, Farlow"'
Autor:
L S, Schneider, D A, Bennett, M R, Farlow, E R, Peskind, M A, Raskind, M, Sano, Y, Stern, S, Haneline, K A, Welsh-Bohmer, J, O'Neil, R, Walter, S, Maresca, M, Culp, R, Alexander, A M, Saunders, D K, Burns, C, Chiang
Publikováno v:
The Journal of Prevention of Alzheimer's Disease.
The onset of mild cognitive impairment (MCI) is an essential outcome in Alzheimer's disease (AD) prevention trials and a compelling milestone for clinically meaningful change. Determining MCI, however, may be variable and subject to disagreement. Adj
Publikováno v:
International journal of clinical practice. 64(2)
To compare the safety and tolerability of switching patients with mild-to-moderate Alzheimer's disease from donepezil to either rivastigmine capsule or transdermal patch.Three studies investigated the switch from donepezil to rivastigmine; study US13
Autor:
M R, Farlow
Publikováno v:
International journal of clinical practice. Supplement. (127)
In the absence of a cure for Alzheimer's disease (AD), treatment has focused on therapy to provide symptomatic benefits and to slow progression of the disease, so that patients can maintain their independence for as long as possible. New research sug
Autor:
M R, Farlow
Publikováno v:
International journal of clinical practice. Supplement. (127)
Autor:
J C, Morris, M R, Farlow, S H, Ferris, A F, Kurz, A, Maelicke, L, Rasmusen, D, Wilkinson, B, Yan
Publikováno v:
Clinical therapeutics. 23
Publikováno v:
Acta neurologica Scandinavica. Supplementum. 176
The extracellular deposition of amyloid beta-peptide (Abeta) in the form of cerebrovascular amyloid and extracellular plaques is one of the major neuropathological manifestations of Alzheimer's disease (AD). Abeta is generated proteolytically from th
Publikováno v:
Neuropsychology. 15(1)
Olfaction is impaired in Alzheimer's disease (AD). It was hypothesized that AD would reduce olfactory-evoked perfusion in mesial temporal olfactory (piriform) cortex, where neuropathology begins. Seven AD patients and 8 elderly controls (ECs) underwe
Autor:
P S, Aisen, K L, Davis, J D, Berg, K, Schafer, K, Campbell, R G, Thomas, M F, Weiner, M R, Farlow, M, Sano, M, Grundman, L J, Thal
Publikováno v:
Neurology. 54(3)
Laboratory and epidemiologic studies suggest that anti-inflammatory/immunosuppressive therapy may be useful in the treatment of AD. In preliminary studies, a regimen of low to moderate dose prednisone was found to suppress peripheral inflammatory mar
Autor:
R C, Dodel, Y, Du, K R, Bales, F, Gao, B, Eastwood, B, Glazier, R, Zimmer, B, Cordell, A, Hake, R, Evans, D, Gallagher-Thompson, L W, Thompson, J R, Tinklenberg, A, Pfefferbaum, E V, Sullivan, J, Yesavage, L, Alstiel, T, Gasser, M R, Farlow, G M, Murphy, S M, Paul
Publikováno v:
Neurology. 54(2)
alpha2 Macroglobulin is a panproteinase inhibitor that is found immunohistochemically in neuritic plaques, a requisite neuropathologic feature of AD. Recently, a pentanucleotide deletion near the 5' end of the "bait region" of the alpha2 macroglobuli
Autor:
P L, Kramer, M, Mineta, C, Klein, K, Schilling, D, de Leon, M R, Farlow, X O, Breakefield, S B, Bressman, W B, Dobyns, L J, Ozelius, A, Brashear
Publikováno v:
Annals of neurology. 46(2)
Rapid-onset dystonia-parkinsonism (RPD) is an autosomal dominant movement disorder characterized by sudden onset of persistent dystonia and parkinsonism, generally during adolescence or early adulthood. Symptoms evolve over hours or days, and general